Background & Aims: Covalent attachment of a 40-kilodalton polyethylene glycol moiety to interferon alpha2a (peginterferon alpha2a) results in sustained delivery and reduced clearance compared with standard interferon alpha2a. The aim of the study was to compare viral kinetics in patients treated with standard or peginterferon alpha2a.
Methods: Patients with chronic hepatitis C were randomly assigned to receive either standard interferon alpha2a thrice weekly (n = 16) or 180 microg peginterferon alpha2a once weekly (n = 17) for 48 weeks. HCV RNA was quantitated before and frequently during treatment.
Results: The extent of the second-phase decline of HCV RNA, representing the degradation rate of infected cells during therapy for responding patients, was 0.02 +/- 0.03 day(-1) (HCV-1), 0.88 +/- 0.64 day(-1) (HCV non-1), 0.06 +/- 0.08 day(-1) (HCV-1), and 0.44 +/- 0.33 day(-1) (HCV non-1) in patients treated with standard or peginterferon alpha2a, respectively. The second-phase decline was low (<0.05 day(-1)) in most patients without a virological end-of-treatment response, and the second-phase decline was high (>0.25 day(-1)) in all patients with sustained virological response.
Conclusions: The degradation rate of infected cells is HCV genotype dependent. Treatment with peginterferon alpha2a may reinforce the death rate of infected cells (particularly in HCV-1-infected patients) or stabilize the therapeutic effect on viral production. The second-phase decline of HCV RNA is predictive of virological sustained response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/gast.2001.24006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicenter retrospective data analysis with 70 patients.
J Dtsch Dermatol Ges
November 2024
Department of Dermatology and Venereology, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Article Synopsis
- Interferon-alpha is crucial for treating cutaneous T-cell lymphomas (CTCL), but the approved version (IFN-α2a) has been unavailable since January 2020, prompting the use of pegylated interferon-α2a (pegIFN-α2a), which is not officially approved for this condition.
- A study involving 70 CTCL patients from twelve German skin centers found a 55.2% overall response rate to pegIFN-α2a, with common adverse effects leading to a 50% discontinuation rate within about 63 weeks.
- The findings suggest that pegIFN-α2a therapy may have similar efficacy and side effects as the discontinued IF
The interferon story continues: EORTC CLTG study explores pegylated interferon α-2a's role in treating mycosis fungoides/Sézary syndrome.
Br J Dermatol
August 2024
University Department for Dermatology, Venerology, Allergology and Phlebology, Skin Cancer Center, Johannes Wesling Medical Center, UKRUB, University of Bochum, Minden, Germany.
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study.
Br J Dermatol
August 2024
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Article Synopsis
- Mycosis fungoides (MF) and Sézary syndrome (SS) are chronic skin cancers that require various treatment strategies; interferon-α (IFN-α) has been used for years, but only the pegylated form, PEG-IFN-α-2a, remains available, though not officially approved for these conditions.
- A study involving 105 patients across 10 countries assessed the effectiveness and safety of PEG-IFN-α-2a, focusing on the time to next treatment (TTNT) as a measure of its clinical benefit.
- Results showed a 53.3% overall response rate with better TTNT for patients receiving combination therapy (10.4 months) compared
Selection of epigenetically privileged HIV-1 proviruses during treatment with panobinostat and interferon-α2a.
Cell
February 2024
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address:
CD4 T cells with latent HIV-1 infection persist despite treatment with antiretroviral agents and represent the main barrier to a cure of HIV-1 infection. Pharmacological disruption of viral latency may expose HIV-1-infected cells to host immune activity, but the clinical efficacy of latency-reversing agents for reducing HIV-1 persistence remains to be proven. Here, we show in a randomized-controlled human clinical trial that the histone deacetylase inhibitor panobinostat, when administered in combination with pegylated interferon-α2a, induces a structural transformation of the HIV-1 reservoir cell pool, characterized by a disproportionate overrepresentation of HIV-1 proviruses integrated in ZNF genes and in chromatin regions with reduced H3K27ac marks, the molecular target sites for panobinostat.
View Article and Find Full Text PDFPredictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment.
Exp Ther Med
December 2023
Department of Gastroenterology and Neurology, Kagawa University Hospital, Kita, Kagawa 761-0793, Japan.
Chronic hepatitis B (CHB) is a major global health concern. Guidelines for the management of hepatitis B virus (HBV) indicate that the loss of hepatitis B surface antigen (HBsAg) is a key endpoint of interest. The present study aimed to examine long-term changes in HBsAg levels in HBV-DNA-negative, hepatitis B e-antigen (HBeAg)-negative patients treated with peginterferon (Peg-IFN) α-2a and nucleos(t)ide analog (NA), and to examine the conditions that make them susceptible to HBsAg decline.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!